Pneumonie à pneumocoques : Questions médicales fréquentes
Nom anglais: Pneumonia, Pneumococcal
Descriptor UI:D011018
Tree Number:C08.730.610.540.550
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Pneumonie à pneumocoques : Questions médicales les plus fréquentes",
"headline": "Pneumonie à pneumocoques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Pneumonie à pneumocoques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-22",
"dateModified": "2025-04-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Pneumonie à pneumocoques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pneumopathie bactérienne",
"url": "https://questionsmedicales.fr/mesh/D018410",
"about": {
"@type": "MedicalCondition",
"name": "Pneumopathie bactérienne",
"code": {
"@type": "MedicalCode",
"code": "D018410",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C08.730.610.540"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Pneumonie à pneumocoques",
"alternateName": "Pneumonia, Pneumococcal",
"code": {
"@type": "MedicalCode",
"code": "D011018",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Antoni Torres",
"url": "https://questionsmedicales.fr/author/Antoni%20Torres",
"affiliation": {
"@type": "Organization",
"name": "Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Xiaohui Fang",
"url": "https://questionsmedicales.fr/author/Xiaohui%20Fang",
"affiliation": {
"@type": "Organization",
"name": "University of California, San Francisco."
}
},
{
"@type": "Person",
"name": "Jeffrey E Gotts",
"url": "https://questionsmedicales.fr/author/Jeffrey%20E%20Gotts",
"affiliation": {
"@type": "Organization",
"name": "University of California, San Francisco."
}
},
{
"@type": "Person",
"name": "Carolyn S Calfee",
"url": "https://questionsmedicales.fr/author/Carolyn%20S%20Calfee",
"affiliation": {
"@type": "Organization",
"name": "University of California, San Francisco."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study.",
"datePublished": "2022-11-16",
"url": "https://questionsmedicales.fr/article/36400662",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.vaccine.2022.11.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pneumococcal urinary antigen testing for antimicrobial guidance in community-acquired pneumonia-A register-based cohort study.",
"datePublished": "2022-05-23",
"url": "https://questionsmedicales.fr/article/35618153",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jinf.2022.05.021"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of severe lymphopenia on the early prediction of clinical outcome in hospitalized patients with pneumococcal community-acquired pneumonia.",
"datePublished": "2023-01-25",
"url": "https://questionsmedicales.fr/article/36694093",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s15010-023-01984-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Community-Acquired Pneumococcal Pneumonia in Highly Vaccinated Population: Analysis by Serotypes, Vaccination Status, and Underlying Medical Conditions.",
"datePublished": "2023-10-30",
"url": "https://questionsmedicales.fr/article/37904655",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3346/jkms.2023.38.e330"
}
},
{
"@type": "ScholarlyArticle",
"name": "Short- and long-term prognosis of patients with community-acquired Legionella or pneumococcal pneumonia diagnosed by urinary antigen testing.",
"datePublished": "2023-06-01",
"url": "https://questionsmedicales.fr/article/37268100",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijid.2023.05.065"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012140"
},
{
"@type": "ListItem",
"position": 3,
"name": "Infections de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012141"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pneumopathie infectieuse",
"item": "https://questionsmedicales.fr/mesh/D011014"
},
{
"@type": "ListItem",
"position": 5,
"name": "Pneumopathie bactérienne",
"item": "https://questionsmedicales.fr/mesh/D018410"
},
{
"@type": "ListItem",
"position": 6,
"name": "Pneumonie à pneumocoques",
"item": "https://questionsmedicales.fr/mesh/D011018"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Pneumonie à pneumocoques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Pneumonie à pneumocoques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-01",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Pneumonie à pneumocoques",
"description": "Comment diagnostiquer une pneumonie à pneumocoques ?\nQuels tests sont utilisés pour confirmer la pneumonie ?\nQuels signes cliniques indiquent une pneumonie à pneumocoques ?\nLa culture de crachats est-elle nécessaire ?\nLes tests sanguins sont-ils utiles ?",
"url": "https://questionsmedicales.fr/mesh/D011018?page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Pneumonie à pneumocoques",
"description": "Quels sont les symptômes courants de la pneumonie à pneumocoques ?\nLa toux est-elle toujours productive ?\nY a-t-il des symptômes atypiques ?\nComment la douleur thoracique se manifeste-t-elle ?\nLes symptômes varient-ils selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D011018?page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Pneumonie à pneumocoques",
"description": "Comment prévenir la pneumonie à pneumocoques ?\nQui devrait se faire vacciner ?\nY a-t-il d'autres mesures préventives ?\nLa vaccination est-elle efficace ?\nÀ quelle fréquence faut-il se faire vacciner ?",
"url": "https://questionsmedicales.fr/mesh/D011018?page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Pneumonie à pneumocoques",
"description": "Quels antibiotiques sont utilisés pour traiter cette pneumonie ?\nLe traitement nécessite-t-il une hospitalisation ?\nDes traitements symptomatiques sont-ils recommandés ?\nCombien de temps dure le traitement antibiotique ?\nDes soins de soutien sont-ils nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D011018?page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Pneumonie à pneumocoques",
"description": "Quelles sont les complications possibles de la pneumonie à pneumocoques ?\nComment l'empyème se développe-t-il ?\nLa pneumonie peut-elle entraîner des problèmes respiratoires chroniques ?\nQuels sont les signes d'une septicémie ?\nLes complications sont-elles plus fréquentes chez certains patients ?",
"url": "https://questionsmedicales.fr/mesh/D011018?page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Pneumonie à pneumocoques",
"description": "Quels sont les principaux facteurs de risque de pneumonie à pneumocoques ?\nLe tabagisme augmente-t-il le risque ?\nLes maladies pulmonaires chroniques sont-elles un facteur de risque ?\nLes enfants sont-ils à risque ?\nL'immunodépression influence-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D011018?page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une pneumonie à pneumocoques ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, les radiographies thoraciques et les cultures de crachats."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer la pneumonie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la radiographie, la tomodensitométrie et les analyses sanguines."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une pneumonie à pneumocoques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, toux productive, douleur thoracique et difficultés respiratoires sont des signes clés."
}
},
{
"@type": "Question",
"name": "La culture de crachats est-elle nécessaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est recommandée pour identifier le pathogène et guider le traitement antibiotique."
}
},
{
"@type": "Question",
"name": "Les tests sanguins sont-ils utiles ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent montrer des signes d'infection et aider à évaluer la gravité."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la pneumonie à pneumocoques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, frissons, toux, douleur thoracique et essoufflement sont fréquents."
}
},
{
"@type": "Question",
"name": "La toux est-elle toujours productive ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, mais elle est souvent accompagnée de mucus purulent dans ce cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes atypiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la confusion ou la fatigue peuvent survenir, surtout chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Comment la douleur thoracique se manifeste-t-elle ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est souvent aiguë et peut s'aggraver lors de la respiration ou de la toux."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes enfants et les personnes âgées peuvent présenter des symptômes moins typiques."
}
},
{
"@type": "Question",
"name": "Comment prévenir la pneumonie à pneumocoques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination est la méthode la plus efficace pour prévenir cette infection."
}
},
{
"@type": "Question",
"name": "Qui devrait se faire vacciner ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les enfants, les personnes âgées et celles avec des maladies chroniques doivent être vaccinés."
}
},
{
"@type": "Question",
"name": "Y a-t-il d'autres mesures préventives ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et maintenir une bonne hygiène respiratoire sont également importants."
}
},
{
"@type": "Question",
"name": "La vaccination est-elle efficace ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle réduit significativement le risque de pneumonie à pneumocoques et ses complications."
}
},
{
"@type": "Question",
"name": "À quelle fréquence faut-il se faire vacciner ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination peut être répétée tous les 5 à 10 ans selon le type de vaccin et l'âge."
}
},
{
"@type": "Question",
"name": "Quels antibiotiques sont utilisés pour traiter cette pneumonie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les pénicillines et les céphalosporines sont couramment prescrites pour traiter l'infection."
}
},
{
"@type": "Question",
"name": "Le traitement nécessite-t-il une hospitalisation ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la gravité des symptômes et de l'état général du patient."
}
},
{
"@type": "Question",
"name": "Des traitements symptomatiques sont-ils recommandés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antipyrétiques et des analgésiques peuvent aider à soulager la fièvre et la douleur."
}
},
{
"@type": "Question",
"name": "Combien de temps dure le traitement antibiotique ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "En général, le traitement dure de 5 à 10 jours, selon la réponse clinique."
}
},
{
"@type": "Question",
"name": "Des soins de soutien sont-ils nécessaires ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hydratation et le repos sont essentiels pour favoriser la guérison."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la pneumonie à pneumocoques ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'empyème, l'abcès pulmonaire et la septicémie."
}
},
{
"@type": "Question",
"name": "Comment l'empyème se développe-t-il ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'empyème se produit lorsque du pus s'accumule dans la cavité pleurale à cause de l'infection."
}
},
{
"@type": "Question",
"name": "La pneumonie peut-elle entraîner des problèmes respiratoires chroniques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des lésions pulmonaires peuvent entraîner des problèmes respiratoires à long terme."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une septicémie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre élevée, confusion, rythme cardiaque rapide et hypotension sont des signes d'alerte."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles plus fréquentes chez certains patients ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées et celles avec des comorbidités sont plus à risque de complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque de pneumonie à pneumocoques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, le tabagisme, et les maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme endommage les voies respiratoires et augmente le risque d'infections."
}
},
{
"@type": "Question",
"name": "Les maladies pulmonaires chroniques sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conditions comme la BPCO augmentent la susceptibilité à la pneumonie."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils à risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes enfants, surtout ceux non vaccinés, sont particulièrement vulnérables."
}
},
{
"@type": "Question",
"name": "L'immunodépression influence-t-elle le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées ont un risque accru de développer des infections pneumococciques."
}
}
]
}
]
}
We aimed to assess the direct protective effect of 13 valent pneumococcal conjugate vaccine (13vPCV) against invasive pneumococcal pneumonia (IPP; including pneumonia and empyema) in children using a ...
Children < 18 years old admitted with pneumonia were eligible for enrolment. IPP was defined as Streptococcus pneumoniae (SP) cultured or detected by polymerase chain reaction (PCR) from blood or pleu...
From February 2015 to September 2018, we enrolled 1,168 children with pneumonia; 779 were 13vPCV-eligible and were individually matched to 15,580 controls. SP was confirmed in 195 IPP cases, 181 of wh...
We failed to identify a strong direct protective effect of 13vPCV against IPP among Australian children, where disease was largely driven by ST3....
To evaluate the effect of pneumococcal urinary antigen test (UAT) usage on broad-spectrum antibiotic treatment in community-acquired pneumonia (CAP)....
Patients admitted to 32 Swedish hospitals between 2011 and 2014 were retrospectively included from the Swedish National Quality Register of CAP. Using propensity score matched data, stratified by CRB-...
UAT was performed for 4,995/14,590 (34.2%) patients, 603/4,995 (12.1%) of whom had positive test results. At day three, performing UAT was not associated with decreased use of BSBM (OR 1.07, 95% CI 0....
Performing UAT had no overall effect on decreasing the use of BSBM treatment by day three of hospitalization, yet non-severely ill patients with positive UAT results were less likely to be treated wit...
To evaluate the impact of an optimal and reproducible cutoff value set according to a predefined lymphopenia scale as an early predictor of in-hospital mortality and other outcomes in patients hospita...
An observational cohort study was conducted based on analysis of a prospective registry of consecutive immunocompetent adults hospitalized for pneumococcal pneumonia in two tertiary hospitals. General...
We included 1173 patients. Lymphopenia on admission was documented in 686 (58.4%). No significant differences were observed between groups regarding the presence of comorbidities. Overall, 299 (25.5%)...
Lymphocyte count < 500/μL could be used as a reproducible predictor of complicated clinical course in patients with an early diagnosis of pneumococcal pneumonia....
Targeted risk population has been highly vaccinated against pneumococcal diseases in South Korea. Despite this, the pneumococcal serotype distribution is evolving, which impedes efficient roll-out of ...
This prospective cohort study included patients aged ≥ 19 years with community-acquired pneumonia (CAP) from five university hospitals in South Korea between September 2018 and July 2021. The outcomes...
A total of 5,009 patients hospitalized with CAP was included (mean age ± standard deviation, 70.3 ± 16.0 years; 3,159 [63.1%] men)....
Serotype 3 and 19A were still the most common serotypes of pCAP in South Korea despite the national immunization program of 13-valent pneumococcal conjugated vaccine in children and PPSV23 in old adul...
To analyze the differences in short- and long-term prognosis and the predictors of survival between patients with community-acquired Legionella and Streptococcus pneumoniae pneumonia, diagnosed early ...
Prospective multicenter study conducted in immunocompetent patients hospitalized with community-acquired Legionella or pneumococcal pneumonia (L-CAP or P-CAP) between 2002-2020. All cases were diagnos...
We included 1452 patients, 260 with community-acquired Legionella pneumonia (L-CAP) and 1192 with community-acquired pneumococcal pneumonia (P-CAP). The 30-day mortality was higher for L-CAP (6.2%) th...
In patients diagnosed early by UAT, the long-term survival after L-CAP or P-CAP was shorter (particularly after P-CAP) than expected, and this shorter survival was mainly associated with age and comor...
Bangladesh introduced the 10-valent pneumococcal conjugate vaccine (PCV10) for children aged < 1 year in March 2015. Previous vaccine effectiveness (VE) studies for pneumonia have used invasive pneumo...
We conducted a matched case-control study between July 2015 and September 2017 in three subdistricts of Sylhet, Bangladesh. Cases were vaccine-eligible children aged 3-35 months with sonographically-c...
We evaluated 8926 children (average age 13.3 months, 58% boys) with clinical pneumonia by ultrasound; 2470 had pneumonia with consolidations ≥ 1 cm; 1893 pneumonia cases were matched with 4238 clinic ...
PCV10 was effective at reducing sonographically-confirmed pneumonia in children aged 3-35 months of age when compared to unvaccinated children. VE increased with the threshold used for consolidation s...
Streptococcus pneumoniae is a global cause of community-acquired pneumonia (CAP) and invasive disease in children. The CAP-IT trial (grant No. 13/88/11; https://www.capitstudy.org.uk/ ) collected naso...
Three-hundred and ninety pneumococci cultured from 1132 nasopharyngeal swabs from 718 children were whole-genome sequenced (Illumina) and tested for susceptibility to penicillin and amoxicillin. Genom...
Among 390 unique pneumococcal isolates, serotypes 15B/C, 11 A, 15 A and 23B1 were most prevalent (n = 145, 37.2%). PCV13 serotypes 3, 19A, and 19F were also identified (n = 25, 6.4%). STs associated w...
Our data suggest that amoxicillin use does not drive pneumococcal serotype prevalence among children in the UK, and prompts consideration of PCVs with additional serotype coverage that are likely to f...
S. pneumoniae (SPN) is the most common cause of pneumonia. The disease can be effectively prevented through immunisation. Since December 2020, the Malaysian Government has included the 10-valent pneum...
MY-Pneumo is a multicentre prospective case-control study conducted in three sentinel sites located in three different states of Peninsular Malaysia - Kuala Lumpur, Pahang, and Kelantan. A cohort of a...
Surveillance data, including carriage rate, serotype variations and the phylogeny data structure of SPN among young children in Malaysia during PCV implementation, will be generated from this study. T...
This project was registered at ClinicalTrials.gov (NCT04923035) on 2021, June 11. The study protocol was approved by the International Medical University Joint-Committee on Research & Ethics (4.15/JCM...
Since 2008 New Zealand has used three different formulations of pneumococcal vaccines on the national infant schedule, PCV7, PCV10 and PCV13, switching between PCV10 and PCV13 twice in 10 years. We ha...
This was a retrospective cohort study using linked administrative data. Outcomes were otitis media, all cause pneumonia and bacterial pneumonia related hospitalisation for children in three cohorts re...
Each observation period, where different vaccine formulations coincided, and therefore comparable with respect to age and the environment, included over fifty-thousand infants and children. PCV10 was ...
These results should offer reassurance about the equivalence of these pneumococcal vaccines against the broader pneumococcal disease outcomes OM and pneumonia....
In the era of childhood pneumococcal conjugate vaccine (PCV) immunization, especially 13-valent pneumococcal conjugate vaccine (PCV13) immunization, serotype replacement of Streptococcus pneumoniae an...
We evaluated pneumococcal vaccine effectiveness in this multicenter, matched case-control study conducted in hospitals and clinics. Cases included patients (aged ≥ 65 years) newly diagnosed with CAP b...
The analysis included 740 individuals (142 patients and 598 controls). The median age of participants was 75 years (men: 54%). The adjusted OR for pneumococcal vaccination against all-cause CAP was 1....
This study was unable to demonstrate the effectiveness of PPSV23 against all-cause and pneumococcal pneumonia after the introduction of childhood PCV13 in Japan. Nonetheless, additional studies are ne...